Page 3 - Narcolepsy Type News Today

30.03.2022 - – Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on ...

9:00 p.m. – 9:05 p.m. Introduction 8:05 a.m. – 8:10 a.m. 9:05 p.m. – 9:10 p.m. Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs Andy Plump, president of Research and Development 8:10 a.m. – 8:35 a.m. 9:10 p.m. – 9:35 p.m. Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection Obi Umeh, global program lead, Rare Genetic and Hematology Therapeutic Area Unit Claus Jepsen, head of Global Pr...